N/A N=125 Families-At-risk for Interstitial Lung Disease Study
Interstitial Lung Disease · Idiopathic Pulmonary Fibrosis
Primary: Number of Participants With ILA (Interstitial Lung Abnormalities) — 85; 13 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=34 The NIH Exercise Therapy for Advanced Lung Disease Trials: Response and Adaptation to Aerobic Exercise in Patients With Interstitial Lung Disease
Interstitial Lung Disease · Idiopathic Pulmonary Fibrosis · Interstitial Pneumonitis
Primary: Change in 6-minute Walk Test Distance (6MWD) — 46.5; 23.2 Meters
Phase 2 N=142 Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
Scleroderma · Interstitial Lung Disease
Primary: Forced Vital Capacity (FVC), as a Percent of the Age, Height, Gender, and Ethnicity Adjusted Predicted Value — 66.52; 66.52; 66.22; 67.03 FVC %-pred — p=0.24
N/A N=25 Rehabilitation of Idiopathic Pulmonary Fibrosis (IPF) Patients
Idiopathic Pulmonary Fibrosis
Primary: 6 Minute Walk Distance — -6.2; -15.3 meters
Phase 3 N=1,178 A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
Lung Diseases, Interstitial
Primary: Absolute Change From Baseline in Forced Vital Capacity (FVC) in Milliliters [mL] at Week 52 — -165.77; -84.64; -98.59 Milliliters (mL) — p=<0.0001
N/A N=114,921 Oxygen Therapy Use in Patients With Fibrotic Interstitial Lung Disease
Lung Diseases, Interstitial
Primary: Time to Oxygen Therapy Initiation — 27.5; NA Months
N/A N=80 Anti-neutrophil Cytoplasmic Antibody in Interstitial Lung Disease.
Interstitial Lung Disease · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Primary: Death From All Causes — 10; 5 Participants
Phase 3 N=158 Scleroderma Lung Disease
Lung Diseases · Pulmonary Fibrosis · Systemic Scleroderma
Primary: Forced Vital Capacity — 66.6; 65.6 % of predicted
N/A N=178 A Study to Characterize the Disease Behavior of Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD) During the Peri-Diagnostic Period
Idiopathic Pulmonary Fibrosis · Interstitial Lung Disease
Primary: Time-Adjusted Semi-Annual Forced Vital Capacity (FVC) Decline in Participants With IPF During the Peri-Diagnostic Period, Measured in Milliliters (mL) by Daily Home…
Phase 2 N=10 Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction
Restrictive Chronic Lung Allograft Dysfunction · Lung Transplant Rejection
Primary: Tolerability of Pirfenidone — 3 Participants
Phase 2 N=253 A Study of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing Interstitial Lung Disease
Lung Diseases, Interstitial
Primary: Rate of Decline in Forced Vital Capacity (FVC) Over the 24-week Double-blind Treatment Period — -17.9; 116.6; -90.3; 125.6 milliliter (mL) — p=0.6777
N/A N=489 An Observational Outcomes Study for Autologous Cell Therapy Among Patients With COPD and Interstitial Lung Disease
COPD · Interstitial Lung Disease
Primary: Change in Quality of Life (QOL) From Baseline — 35.35; 27.96; 26.87 score on a scale
Phase 3 N=81 A Study to Test How Well a Medicine Called Nintedanib Helps People in China With Progressive Lung Fibrosis
Lung Diseases, Interstitial
Primary: Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks Expressed in Milliliter (mL) — -191.89; -85.32 Milliliter/year
Phase 3 N=663 Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
Lung Diseases, Interstitial
Primary: Annual Rate of Decline in Forced Vital Capacity - Overall Population — -80.82; -187.78 Milliliter per year — p=<.0001
Phase 3 N=236 Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF
Pulmonary Fibrosis
Primary: Overall Change in Forced Vital Capacity — -0.18; -0.19 liters
N/A N=207 Autologous Stem Cell Treatment for Chronic Lung Disease Study
COPD · Interstitial Lung Disease
Primary: Change in FEV1 From Baseline Among COPD Patients — 12.8 percentage of change in FEV1
Phase 2 N=51 Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate
Scleroderma, Systemic · Interstitial Lung Disease
Primary: Percent Predicted Forced Vital Capacity (FVC-%) — 2.24; 2.09 percent predicted — p=0.9326
Phase 3 N=10 Rituximab in Rheumatoid Arthritis Lung Disease
Rheumatoid Arthritis · Interstitial Pneumonia
Primary: Change in Diffusion Capacity for Carbon Monoxide (DLco) From Baseline to 48 Weeks — 4; 2; 1 participants
Phase 2 N=15 Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension · Interstitial Lung Disease · Idiopathic Pulmonary Fibrosis
Primary: 6 Minute Walk Distance — 230 meters
Phase 4 N=103 The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19
Pulmonary Fibrosis · Interstitial Lung Disease · Respiratory Disease
Primary: Change in Forced Vital Capacity (FVC) — 147.55; 167.72 mL
Phase 2 N=20 Abatacept for the Treatment of Myositis-associated Interstitial Lung Disease
Myositis · Interstitial Lung Disease
Primary: % Predicted Forced Vital Capacity (FVC) Absolute Change — -1.70; -2.05 % predicted FVC — p=<0.05
N/A N=34,960 Study of Progression to Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Incidence/Management and Treatment
Lung Diseases, Interstitial
Primary: Incidence Probability of Progression to Pulmonary Fibrosing-Interstitial Lung Disease (PF-ILDs) — 0.147; 0.249; 0.334; 0.395 Cumulative incidence probability
N/A N=108 INREAL - Nintedanib for Changes in Dyspnea and Cough in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease (ILD) With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation
Lung Diseases, Interstitial
Primary: Correlation Between Change From Baseline to Week 52 in Forced Vital Capacity (FVC) [% Predicted] and Change From Baseline to Week 52 in Dyspnea Symptom Score — -0.2576…
Phase 2 N=10 Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809)
Idiopathic Pulmonary Fibrosis
Primary: Primary Outcome — -0.0147; 0.0740 Unitless
Phase 3 N=1,177 A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis
Primary: Absolute Change From Baseline in Forced Vital Capacity (FVC) [mL] at Week 52 — -183.48; -138.60; -114.65 Milliliters (mL) — p=0.0222
Early Phase 1 N=17 Characterization of Tissue-Specific Immune Responses to Bronchoscopic Instillation of Mycobacterial Antigens Into the Human Lung
Healthy · Latent Tuberculosis Infection (LTBI)
Primary: Median Difference in CD4 Cell Response to Intrabronchial Instillation of Tuberculin Purified Protein Derivative (PPD) — 5.26; 0.725; 29.9; 2.92 % Antigen Specific T…
Early Phase 1 N=35 Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis.
Idiopathic Pulmonary Fibrosis
Primary: EGCG PK Level in Healthy Volunteers — NA; NA; NA; 861 nM
Phase 3 N=54 A Study to Evaluate Long-term Safety of Nintedanib in Children and Adolescents With Interstitial Lung Disease (InPedILD®-ON)
Lung Diseases, Interstitial
Primary: Number of Patients With Treatment-emergent Adverse Events (AEs) Over the Whole Trial — 53 Participants
N/A N=408 Post-marketing Surveillance of Ofev Capsules in Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype in Japan
Lung Diseases, Interstitial
Primary: Incidence of Adverse Drug Reactions (ADRs) — 246 Participants
Phase 2 N=147 A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis
Primary: The Change From Baseline in Forced Vital Capacity (FVC) at 12 Weeks — -77.70; 2.72; -95.62; 6.10 Milliliter